ProQR Therapeutics (PRQR) Non-Current Debt (2016 - 2023)
ProQR Therapeutics (PRQR) posted Non-Current Debt of $4.6 million for Q4 2023, up 46.74% sequentially from $3.1 million in Q3 2023, and up 5.98% YoY from $4.4 million in Q4 2022.
ProQR Therapeutics (PRQR) Non-Current Debt (2016 - 2023) Analysis & Trends
ProQR Therapeutics has reported Non-Current Debt for 8 years, with the latest figure at $4.6 million in Q4 2023.
- Quarterly Non-Current Debt rose 5.98% year-over-year to $4.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.6 million (up 5.98% YoY) and the FY2023 annual result came in at $4.6 million, up 5.98% from the prior year.
- Non-Current Debt grew to $4.6 million in Q4 2023 per PRQR's latest filing, from $3.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $45.0 million in Q4 2021 and troughed at $3.1 million in Q3 2023.
- A 5-year average of $16.1 million and a median of $12.9 million in 2019 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2021 and 2023: Non-Current Debt jumped 278.77% in 2021, then plunged 90.34% in 2023.
- Over 5 years, Non-Current Debt stood at $14.1 million in 2019, then soared by 37.21% to $19.3 million in 2020, then surged by 133.03% to $45.0 million in 2021, then slumped by 90.31% to $4.4 million in 2022, then gained by 5.98% to $4.6 million in 2023.
- According to Business Quant data, Non-Current Debt over the past three periods registered $4.6 million, $3.1 million, and $3.9 million for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.62 Mn |
| Sep 30, 2023 | 3.15 Mn |
| Jun 30, 2023 | 3.89 Mn |
| Mar 31, 2023 | 4.19 Mn |
| Dec 31, 2022 | 4.36 Mn |
| Sep 30, 2022 | 4.81 Mn |
| Jun 30, 2022 | 40.31 Mn |
| Mar 31, 2022 | 43.06 Mn |
| Dec 31, 2021 | 44.98 Mn |
| Sep 30, 2021 | 20.65 Mn |
| Jun 30, 2021 | 20.44 Mn |
| Dec 31, 2020 | 19.30 Mn |
| Sep 30, 2020 | 19.36 Mn |
| Jun 30, 2020 | 5.40 Mn |
| Mar 31, 2020 | 14.50 Mn |
| Dec 31, 2019 | 14.07 Mn |
| Sep 30, 2019 | 11.69 Mn |
| Jun 30, 2019 | 11.64 Mn |
| Dec 31, 2018 | 10.71 Mn |
| Jun 30, 2018 | 7.19 Mn |